- Trials with a EudraCT protocol (66)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
66 result(s) found for: Cell surface markers.
Displaying page 1 of 4.
EudraCT Number: 2022-001585-36 | Sponsor Protocol Number: AMC_SMILE_1.0 | Start Date*: 2022-07-05 | |||||||||||
Sponsor Name:Amsterdam UMC | |||||||||||||
Full Title: EffectS of L-glutaMIne on oxIdative stress, sickLE erythrocyte viability, inflammation and endothelial activity in sickle cell disease (SMILE trial) | |||||||||||||
Medical condition: Sickle Cell Disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000581-10 | Sponsor Protocol Number: 12OY006 | Start Date*: 2013-07-25 | |||||||||||
Sponsor Name:Nottingham University NHS Trust | |||||||||||||
Full Title: Evaluation of inflammatory markers in patients on topical anti-glaucoma drop therapy; a comparative trial of preserved and non-preserved primary medical treatment (eye drops) in patients with glauc... | |||||||||||||
Medical condition: Glaucoma is the condition that is being treated by these eye drops - however the study is aimed at measuring the amount of inflammation that develops on the surface of the eye when these drops are ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000411-91 | Sponsor Protocol Number: NKZellen-Version1.0 | Start Date*: 2013-02-13 |
Sponsor Name:Charité - Universitätsmedizin Berlin | ||
Full Title: Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod: a monocentric, prospective, one year, baseline-to-treatment, open-label, single group pilot trial | ||
Medical condition: relapsing-remitting multiple sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-017525-19 | Sponsor Protocol Number: 77777 | Start Date*: 2010-03-12 |
Sponsor Name:St. Vincents University Hospital, Department of Rheumatology. | ||
Full Title: Abatacept in Psoriasis and Psoriatic Arthritis: a single centre, placebo-controlled, crossover study in 15 patients. | ||
Medical condition: Psoriatic Arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002733-10 | Sponsor Protocol Number: Dual-Triple-ART | Start Date*: 2019-08-13 | |||||||||||
Sponsor Name:FUNDACIÓ LLUITA CONTRA LA SIDA | |||||||||||||
Full Title: Exploratory, open-label, randomized clinical trial to assess the efficacy of first-line dual vs. triple antiretroviral therapy (art) in hiv-1 reservoir and in peripheral compartments in hiv-infecte... | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001775-20 | Sponsor Protocol Number: CHDR1644 | Start Date*: 2018-07-12 |
Sponsor Name:Centre for Human Drug Research | ||
Full Title: Immunomonitoring of tacrolimus in healthy volunteers | ||
Medical condition: Immunesuppression | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-004995-17 | Sponsor Protocol Number: NL7507301820 | Start Date*: 2021-03-11 |
Sponsor Name:AMsterdam UMC-AMC | ||
Full Title: Low dose iron chelation as TReatment of Oxidative stress in Sickle cell disease; TROS study | ||
Medical condition: Sickle cell disease (an hereditary hemoglobinopathy) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-003217-33 | Sponsor Protocol Number: ViDImmun | Start Date*: 2013-02-04 | |||||||||||
Sponsor Name:Charité - Universitätsmedizin Berlin | |||||||||||||
Full Title: Immunological response of a single dose of 100,000 I.U. of cholecalciferol (vitamin D3) | |||||||||||||
Medical condition: relative vitamin D3 deficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002894-36 | Sponsor Protocol Number: IXIARO-booster-senescence | Start Date*: 2017-12-22 |
Sponsor Name:Medical University of Vienna (MUW) | ||
Full Title: "An open, monocentric, uncontrolled phase 4 trial to characterise cellular and humoral immune responses following the first booster immunisation with the inactivated, purified Japanese Encephalitis... | ||
Medical condition: The condition under investigation is the naturally aging immune system. The aim of this study is to investigate the immune responses following a booster immunisation with the Japanese Encephalitis ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001971-61 | Sponsor Protocol Number: SALYCENDO | Start Date*: 2016-08-29 |
Sponsor Name:Radboudumc | ||
Full Title: The effects of acetylsalicylic acid on immunoparalysis following human endotoxemia. | ||
Medical condition: We will investigate the effects of acetylsalicylic acid on immunoparalysis following human endotoxemia in healthy male volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-005024-10 | Sponsor Protocol Number: I6F-MC-JJCB | Start Date*: 2015-07-29 |
Sponsor Name:Eli Lilly and Company | ||
Full Title: A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination with Dexamethasone in T-ALL/T-LBL Patients | ||
Medical condition: T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) SE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-002735-23 | Sponsor Protocol Number: IPROTECT1 | Start Date*: 2013-12-04 | |||||||||||
Sponsor Name:InnaVirVax SA | |||||||||||||
Full Title: Assessment of the therapeutic properties of the VAC-3S immunoprotective vaccine when combined with standard antiretroviral therapy (ART) in the course of HIV-1 infection. A European multicenter, r... | |||||||||||||
Medical condition: Chronically infected HIV-1 patients under viral control on Anti-Retroviral therapy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005791-32 | Sponsor Protocol Number: HF0220/003 | Start Date*: 2006-04-24 | |||||||||||
Sponsor Name:Hunter-Fleming Ltd | |||||||||||||
Full Title: Chemical Safety/Tolerability of HF0220 and its Effect on Biochemical Markers Relevant to Patients with a Diagnosis of Mild to Moderate Alzheimer's Disease. | |||||||||||||
Medical condition: HF0220 experimentally appears to exert its potential beneficial effects within the CNS and possibly other tissues by attenuating the adverse effects of oxidative stress. It is believed that this me... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000308-12 | Sponsor Protocol Number: P150941J | Start Date*: 2020-11-06 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS | |||||||||||||
Full Title: « Mesenchymal stromal cells treatment in Lyell syndrome: A pilot phase 1-2 open trial” | |||||||||||||
Medical condition: Patients: Adults diagnosed with SJS-TEN with at least 10% of body surface area involved. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002528-34 | Sponsor Protocol Number: HO158 | Start Date*: 2020-10-01 | |||||||||||
Sponsor Name:HOVON Foundation | |||||||||||||
Full Title: First line treatment with VeNEtoclaX and ibruTinib induction followed by obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients not in complete remission and/or with detectable bone marrow mi... | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022681-27 | Sponsor Protocol Number: O-DEX-1 | Start Date*: 2010-11-09 |
Sponsor Name:University Hospital Brno | ||
Full Title: Ofatumumab Added to Dexamethasone in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia | ||
Medical condition: Patients with refractory/relapsed CLL | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000201-72 | Sponsor Protocol Number: 1 | Start Date*: 2012-05-11 |
Sponsor Name:University of Aberdeen [...] | ||
Full Title: The Effects of Inorganic Nitrite on cardiac and skeletal muscle: Physiology, Pharmacology and Therapeutic Potential. Peripheral Arterial Disease | ||
Medical condition: Peripheral arterial Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2005-004313-15 | Sponsor Protocol Number: NI-0401-01 | Start Date*: 2006-07-14 |
Sponsor Name:NovImmune S.A. | ||
Full Title: A Phase I/IIa, Double-blind, Randomized, Placebo-controlled, Dose-Escalation Study of NI-0401 in Patients with Moderate to Severe Active Crohn´s Disease | ||
Medical condition: Moderate to Severe Active Crohn´s Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2009-011538-93 | Sponsor Protocol Number: Maraviroc –switch | Start Date*: 2010-06-07 |
Sponsor Name:Imperial College London | ||
Full Title: A prospective, randomised study to access safety, changes in platelet reactivity, plasma cardiac biomarkers and metabolic parameters over 48 weeks in HIV-1 infected subjects undergoing a switch in... | ||
Medical condition: HIV | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IE (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-004501-24 | Sponsor Protocol Number: CT-2011-01 | Start Date*: 2012-03-06 | |||||||||||
Sponsor Name:CureTech Ltd. | |||||||||||||
Full Title: Phase II study to evaluate the safety, tolerability and efficacy of CT-011 administered intravenously to patients with metastatic melanoma | |||||||||||||
Medical condition: Metastatic melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
